Document Detail


The Saudi Project for Assessment of Coronary Events (SPACE) registry: design and results of a phase I pilot study.
MedLine Citation:
PMID:  19584982     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The delay between the availability of clinical evidence and its application to the care of patients with acute coronary syndrome (ACS) in the Kingdom of Saudi Arabia remains undefined. The Saudi Project for Assessment of Coronary Events (SPACE) registry provides a comprehensive view of the current diagnostic and treatment strategies for patients with ACS; thus, the registry may be used to identify opportunities to improve the care of these patients. METHODS: Eight hospitals in different regions of Saudi Arabia were involved in the pilot phase of the registry, from December 2005 to July 2006. The study patients included individuals with ST segment elevation myocardial infarction (STEMI), non-STEMI and unstable angina. RESULTS: A total of 435 patients (77% men and 80% Saudis) with a mean age of 57.1 years were enrolled. Medical history included previously diagnosed ischemic heart disease (32%), percutaneous coronary intervention (12%), diabetes mellitus (53%), hypertension (48%), current smoking (39%), hyperlipidemia (31%) and family history of premature coronary artery disease (11%). The median door-to-needle time for fibrinolytic therapy received by patients with STEMIs was 90 min. Inhospital medications included acetylsalicylic acid (98%), clopidogrel (73%), angiotensin- converting enzyme inhibitors (74%), beta-blockers (73%), statins (88%), unfractionated heparin (80%), low-molecular weight heparin (22%) and glycoprotein IIb/IIIa inhibitors (9%). The inhospital mortality rate was 5%. CONCLUSION: The first nationwide registry of patients with ACS in the Kingdom of Saudi Arabia is presented. In contrast to registries from developed countries, our cohort is characterized by a younger age at presentation and a much higher prevalence of diabetes mellitus. Most patients with STEMIs did not receive fibrinolytic therapy within the time recommended in the American College of Cardiology/American Heart Association guidelines. The results of the present pilot study show potential targets for improvement in care.
Authors:
Khalid F AlHabib; Ahmad Hersi; Hussam AlFaleh; Mohammad Kurdi; Mohammad Arafah; Mostafa Youssef; Khalid AlNemer; Anas Bakheet; Ayed AlQarni; Tariq Soomro; Amir Taraben; Asif Malik; Waqar Habib Ahmed
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Canadian journal of cardiology     Volume:  25     ISSN:  1916-7075     ISO Abbreviation:  Can J Cardiol     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-07-08     Completed Date:  2009-07-31     Revised Date:  2010-09-24    
Medline Journal Info:
Nlm Unique ID:  8510280     Medline TA:  Can J Cardiol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  e255-8     Citation Subset:  IM    
Affiliation:
King Fahad Cardiac Centre, College of Medicine, King Saud University, Riyadh 11472, Saudi Arabia. khalidalhabib13@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / diagnosis,  drug therapy*,  mortality
Female
Fibrinolytic Agents / therapeutic use
Guideline Adherence
Hospital Mortality
Humans
Male
Middle Aged
Pilot Projects
Practice Guidelines as Topic
Registries
Saudi Arabia / epidemiology
Time Factors
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of interleukin-15 on the course of myocarditis in Coxsackievirus B3-infected BALB/c mice.
Next Document:  Hypertrophic obstructive cardiomyopathy complicated by ruptured chordae tendineae to the posterior m...